Supernus Pharmaceuticals (SUPN) Enterprise Value (2011 - 2026)
Supernus Pharmaceuticals (SUPN) reported Enterprise Value of -$384.2 million for Q1 2026, up 17.12% year-over-year from -$328.1 million in Q1 2025, and down 24.48% quarter-over-quarter from -$308.7 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Enterprise Value (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 16 years of Enterprise Value data on file, last reported at -$384.2 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$384.2 million, up 17.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$384.2 million (up 17.12% YoY), and the FY2025 annual result was -$308.7 million, up 31.95% from the prior year.
- Enterprise Value declined to -$384.2 million in Q1 2026 per SUPN's latest filing, from -$308.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$151.7 million in Q2 2023 and troughed at -$522.6 million in Q2 2025.
- A 5-year average of -$342.6 million and a median of -$347.2 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 57.97% in 2023, then tumbled 128.93% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$461.3 million in 2022, then jumped by 44.75% to -$254.9 million in 2023, then tumbled by 77.97% to -$453.6 million in 2024, then soared by 31.95% to -$308.7 million in 2025, then decreased by 24.48% to -$384.2 million in 2026.
- Business Quant data shows SUPN's Enterprise Value at -$384.2 million in Q1 2026, -$308.7 million in Q4 2025, and -$281.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -3.74 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -1.94 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -2.15 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -77.77 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | -1.32 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -428.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -511.86 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -498.58 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -750.88 Mn |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | -384.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -384.24 Mn |
| Dec 31, 2025 | -308.67 Mn |
| Sep 30, 2025 | -281.16 Mn |
| Jun 30, 2025 | -522.60 Mn |
| Mar 31, 2025 | -463.59 Mn |
| Dec 31, 2024 | -453.61 Mn |
| Sep 30, 2024 | -403.21 Mn |
| Jun 30, 2024 | -347.19 Mn |
| Mar 31, 2024 | -297.74 Mn |
| Dec 31, 2023 | -254.87 Mn |
| Sep 30, 2023 | -200.19 Mn |
| Jun 30, 2023 | -151.66 Mn |
| Mar 31, 2023 | -228.57 Mn |
| Dec 31, 2022 | -461.33 Mn |
| Sep 30, 2022 | -391.79 Mn |
| Jun 30, 2022 | -360.79 Mn |
| Mar 31, 2022 | -312.20 Mn |
| Dec 31, 2021 | -339.68 Mn |
| Sep 30, 2021 | -443.85 Mn |
| Jun 30, 2021 | -409.84 Mn |